Your browser doesn't support javascript.
loading
Effect of thalidomide on bone marrow angiogenesis in multiple myeloma patients.
Cury, Priscilla Cury de Camargo; Higashi, Fabiana; Zacchi, Flávia Fernandes Silva; Palhares, Renata Bacic; Quero, Adriana Alvares; Dias, Ana Luiza Miranda Silva; Crusoé, Edvan de Queiroz; Hungria, Vania Tietsche de Moraes.
Afiliação
  • Cury PCC; Faculdade de Ciências Médicas da Santa Casa de São Paulo (FCMSCSP), São Paulo, SP, Brazil; Clínica São Germano São Paulo, SP, Brazil. Electronic address: pricury@yahoo.com.
  • Higashi F; Faculdade de Ciências Médicas da Santa Casa de São Paulo (FCMSCSP), São Paulo, SP, Brazil; Clínica São Germano São Paulo, SP, Brazil.
  • Zacchi FFS; Laboratório Fleury, São Paulo, SP, Brazil.
  • Palhares RB; Instituto de infectologia Emílio Ribas, São Paulo, SP, Brazil.
  • Quero AA; Faculdade de Ciências Médicas da Santa Casa de São Paulo (FCMSCSP), São Paulo, SP, Brazil.
  • Dias ALMS; Faculdade de Ciências Médicas da Santa Casa de São Paulo (FCMSCSP), São Paulo, SP, Brazil.
  • Crusoé EQ; Universidade da Bahia (UFBA), Salvador, BA, Brazil; Clínica CEHON Rede oncologia D'or, Salvador, BA, Brazil.
  • Hungria VTM; Faculdade de Ciências Médicas da Santa Casa de São Paulo (FCMSCSP), São Paulo, SP, Brazil; Clínica São Germano São Paulo, SP, Brazil.
Hematol Transfus Cell Ther ; 42(2): 159-163, 2020.
Article em En | MEDLINE | ID: mdl-31519532
BACKGROUND: Bone marrow angiogenesis is increased in multiple myeloma (MM) patients, prompting the rationale for using antiangiogenic drugs in the treatment of these patients. OBJECTIVE: To assess angiogenesis in patients with MM at diagnosis and following treatment with an antiangiogenic drug. PATIENTS AND METHODS: Twenty-three patients with newly diagnosed MM were treated with thalidomide-based regimens. Bone marrow evaluation was made before and following treatment and included angiogenesis assessment, which was quantified through microvessel density (MVD) determination, by means of anti-CD34 immunohistochemical labeling, and classified either as high MVD or low MVD, according to the mean CD34 count: above or below the median of 12.6. RESULTS: The pre-therapy median MVD was 12 (7.5-18.3) versus 8.7 (5.35-18.5) post-therapy, p=0.2114. CONCLUSIONS: Our study found no reduction in MVD before and following treatment and, accordingly, we could establish no relationship between MVD and response to therapy in the sample we studied.
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Hematol Transfus Cell Ther Ano de publicação: 2020 Tipo de documento: Article País de publicação: Brasil
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Hematol Transfus Cell Ther Ano de publicação: 2020 Tipo de documento: Article País de publicação: Brasil